silver sulfadiazine 1% cream

Manufacturer
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC
Effective date
2012-05-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3792
Source
full-release
Hydrated at
2026-05-31 20:15:02

Label at a glance#

ProductSilver Sulfadiazine
Active ingredientSILVER SULFADIAZINE
Label structure12 sections

Indications and uses

Silver sulfadiazine 1% cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.

Dosage and administration

Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided, and SILVADENE Cream 1% (silver sulfadiazine) is applied under sterile conditions. The burn areas should be covered with Silver sulfadiazine 1% cream at all times. The cream should be applied once to twice daily to a thickness of...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Silver sulfadiazine 1% cream is a soft, white, water-miscible cream containing the antimicrobial agent silver sulfadiazine in micronized form, which has the following structural formula:

STRUCTURAL FORMULA
STRUCTURAL FORMULA

Each gram of silver sulfadiazine 1% cream contains 10 mg of micronized silver sulfadiazine. The cream vehicle consists of CETYL ALCOHOL, ISOPROPYL MYRISTATE, POLYOXYL 40 STEARATE, PROPYLENE GLYCOL, WATER, STEARYL ALCOHOL, SODIUM HYDROXIDE, SORBITAN MONOOLEATE, PETROLATUM, METHYLPARABEN. SILVADENE Cream 1% (silver sulfadiazine) spreads easily and can be washed off readily with water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below.

Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine.

Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect.

Results of In Vitro Testing with Silvadene® Cream 1% (silver sulfadiazine) Concentration of Silver Sulfadiazine Number of Sensitive Strains/Total Number of Strains Tested
Genus & Species 50 μg/mL 100 μg/mL
Pseudomonas
aeruginosa 130/130 130/130
Xanthomonas (Pseudomonas)
maltophilia 7/7 7/7
Enterobacter species 48/50 50/50
Enterobacter cloacae24/24 24/24
Klebsiella species 53/54 54/54
Escherichia coli63/63 63/63
Serratia species 27/28 28/28
Proteus mirabilis53/53 53/53
Morganella morganii10/10 10/10
Providencia rettgeri2/2 2/2
Providencia species 1/1 1/1
Proteus vulgaris2/2 2/2
Citrobacter species 10/10 10/10
Acinetobacter
calcoaceticus 10/11 11/11
Staphylococcus aureus100/101 100/101
Staphylococcus
epidermidis 51/51 51/51
β-Hemolytic
Streptococcus 4/4 4/4
Enterococcus species 52/53 53/53
Corynebacterium-
diphtheriae 2/2 2/2
Clostridium perfringens0/2 2/2
Candida albicans43/50 50/50

Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Silver sulfadiazine 1% cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Silver sulfadiazine 1% cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.

Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver sulfadiazine 1% cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

WARNINGS

WARNINGS SECTION

There is potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction.

Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low.

The use of Silver sulfadiazine 1% cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

If hepatic and renal functions become impaired and elimination of drug decreases, accumulation may occur and discontinuation of Silver sulfadiazine 1% cream should be weighed against the therapeutic benefit being achieved.

In considering the use of topical proteolytic enzymes in conjunction with Silver sulfadiazine 1% cream, the possibility should be noted that silver may inactivate such enzymes.

Laboratory Tests

LABORATORY TESTS SECTION

In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 mg% to 12 mg%). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term dermal toxicity studies of 24 months' duration in rats and 18 months' in mice with concentrations of silver sulfadiazine three to ten times the concentration in Silver sulfadiazine 1% cream revealed no evidence of carcinogenicity.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects.

TERATOGENIC EFFECTS SECTION

Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in SILVADENE Cream 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term. (See CONTRAINDICATIONS.)

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether silver sulfadiazine is excreted in human milk. However, sulfonamides are known to be excreted in human milk, and all sulfonamide derivatives are known to increase the possibility of kernicterus. Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Geriatric Use

GERIATRIC USE SECTION

Of the total number of subjects in clinical studies of Silver sulfadiazine 1% cream, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established. (See CONTRAINDICATIONS.)

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy.1,2,3 Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within 2 to 4 days of initiation of therapy. Rebound to normal leukocyte levels follows onset within 2 to 3 days. Recovery is not influenced by continuation of silver sulfadiazine therapy. An increased incidence of leukopenia has been reported in patients treated concurrently with cimetidine.

Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis.

Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial-thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture.

Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions, which have been associated with sulfonamides, are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including Stevens-Johnson syndrome and exfoliative dermatitis; gastrointestinal reactions; hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided, and SILVADENE Cream 1% (silver sulfadiazine) is applied under sterile conditions. The burn areas should be covered with Silver sulfadiazine 1% cream at all times. The cream should be applied once to twice daily to a thickness of approximately 1/16 inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings necessary, they may be used.

Reapply immediately after hydrotherapy.

Treatment with Silver sulfadiazine 1% cream should be continued until satisfactory healing has occurred, or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

HOW SUPPLIED

HOW SUPPLIED SECTION

Silver sulfadiazine 1% creamis supplied by Keltman Pharmaceuticals Inc. as follows:

NDCStrengthQuantity/FormColorSource Prod. Code
68387-450-0110 mg/1 g50 Grams in a Jarwhite to off-white00591-0810

REFERENCES

REFERENCES SECTION

  1. Caffee F, Bingham H. Leukopenia and silver sulfadiazine. J Trauma. 1982;22: 586–587.
  2. Jarret F, Ellerbe S, Demling R. Acute leukopenia during topical burn therapy with silver sulfadiazine. Amer J Surg. 1978;135:818–819.
  3. Kiker RG, Carvajal HF, Micak RP, Larson DL. A controlled study of the effects of silver sulfadiazine on white blood cell counts in burned children. J Trauma. 1977; 17:835–836.

Prescribing Information as of July 2003.

SPL UNCLASSIFIED SECTION

Manufactured for Watson Laboratories, Inc.
Corona, CA 92880 USA
Manufactured by Dr. Reddy’s Laboratories Louisiana, LLC
Shreveport, LA 71106

Image of Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Image of labelImage of label

Image of Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Image of LabelImage of Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
106351silver sulfADIAZINE 1 % Topical CreamPSN3792
106351silver sulfadiazine 10 MG/ML Topical CreamSCD3792
106351silver sulfadiazine 1 % Topical CreamSY3792

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SILVER SULFADIAZINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeQR Code49999018525\LOT\EXPSilverSulfadiazine25gDrReddys.jpg
Data codeQR Code49999018550\LOT\EXPSilverSulfadiazine50gDrReddys.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6cca4355-1206-91f7-02de-17eef38a8622Product name120140508
751c581a-bf64-2fd7-b3ec-ca02c83e4a00Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
49999-185-25Silver Sulfadiazine25 g in 1 TUBECREAM253792
49999-185-50Silver Sulfadiazine50 g in 1 JARCREAM503792

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
49999-185SILVER SULFADIAZINE CREAM [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3792Legacy NDC, 2 package rows20120502_f81457dc-2671-458f-8ed5-b45528e6aa17.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
49999-185-25GM - Gram49999-1852f7d17c9-282f-4779-90ea-ca64912c439912013-02-13
49999-185-50GM - Gram49999-18549777b8b-d1ac-4385-bd6c-cc3c75deb54c12013-02-13
0591-0810-46GM - Gram0591-0810cd3b3b95-f135-4610-8240-92faddbae0e912012-07-24
0591-0810-55GM - Gram0591-08108793ecb3-3e64-4803-8cb4-35408fd2e1f212012-07-24
0591-0810-83GM - Gram0591-08103895fb01-d2a0-4df7-8422-ccf8b5aac89712012-07-24
0591-0810-85GM - Gram0591-0810d661cd6d-d087-458e-a5d9-b49bc7ed2c8e12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SILVER SULFADIAZINEACTIVE INGREDIENTW46JY43EJR3792
SILVER SULFADIAZINEACTIVE MOIETYW46JY43EJR3792
CETYL ALCOHOLINACTIVE INGREDIENT936JST6JCN3792
ISOPROPYL MYRISTATEINACTIVE INGREDIENT0RE8K4LNJS3792
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T3792
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U3792
POLYOXYL 40 STEARATEINACTIVE INGREDIENT13A4J4NH9I3792
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V33792
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I3792
SORBITAN MONOOLEATEINACTIVE INGREDIENT06XEA2VD563792
STEARYL ALCOHOLINACTIVE INGREDIENT2KR89I4H1Y3792
WATERINACTIVE INGREDIENT059QF0KO0R3792

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
49999-18549999-185-50, 49999-185-25
0591-0810

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 8 · 431 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PETROLATUMPETROLATUM4T6H12BN9UCAPSULE / VAGINALNAExact identifier — unii candidate
18 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / VAGINAL4084 mgExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TDROPS / AURICULAR (OTIC)0.01 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IMOUTHWASH / BUCCAL2 mg/1mlExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SHAMPOO, SUSPENSION / TOPICAL2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRASPINALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSGEL / TOPICAL29 mgExact identifier — unii candidate
18 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, EMULSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, EXTENDED RELEASE / TRANSDERMAL58.13 mgExact identifier — unii candidate
81 equally ranked IID candidates
STEARYL ALCOHOLSTEARYL ALCOHOL2KR89I4H1YCAPSULE, EXTENDED RELEASE / ORAL72 mgExact identifier — unii candidate
12 equally ranked IID candidates
SORBITAN MONOOLEATESORBITAN MONOOLEATE06XEA2VD56TABLET, FILM COATED, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
16 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3PASTE / DENTAL0.5 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / TOPICAL39 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SOFT TISSUEADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS15 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TELIXIR / ORAL800 mgExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / SUBCUTANEOUSNAExact identifier — unii candidate
174 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNTABLET, COATED / ORAL0.25 mgExact identifier — unii candidate
20 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICONCENTRATE / ORAL10 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / INTRAVENOUS45 mgExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / RETROBULBARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TOINTMENT / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / DENTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / IRRIGATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR27 mgExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCONCENTRATE / ORAL12 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY / SUBLINGUAL36 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM / TOPICAL76000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION, CONCENTRATE / ORAL2590 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / ORAL27120 mgExact identifier — unii candidate
81 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNTABLET, ORALLY DISINTEGRATING / ORAL9 mgExact identifier — unii candidate
20 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNSUSPENSION / AURICULAR (OTIC)1 %w/vExact identifier — unii candidate
20 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM / TOPICAL3000 mgExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IAEROSOL, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / VAGINAL0.1 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-AMNIOTICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / NASAL250 mgExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNAEROSOL / TOPICAL1.16 %w/wExact identifier — unii candidate
20 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNTABLET, FILM COATED / ORALNAExact identifier — unii candidate
20 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION/ DROPS / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SYSTEM / TOPICAL4200 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LIQUID / RESPIRATORY (INHALATION)10 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IAEROSOL, FOAM / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISHAMPOO / TOPICAL77 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IELIXIR / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM, AUGMENTED / TOPICAL278 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS78.36 mgExact identifier — unii candidate
174 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
STEARYL ALCOHOLSTEARYL ALCOHOL2KR89I4H1YTABLET, EXTENDED RELEASE / ORAL244 mgExact identifier — unii candidate
12 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
CETYL ALCOHOLCETYL ALCOHOL936JST6JCNCAPSULE, DELAYED RELEASE / ORAL59 mgExact identifier — unii candidate
20 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 2 matching rows.

Source provenance: Browse the complete Orange Book source catalog.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018578-001SSDSILVER SULFADIAZINE1%CREAM / TOPICALABRLD, RS1982-02-25
N018578-003SSD AFSILVER SULFADIAZINE1%CREAM / TOPICAL1990-07-11

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N018578-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25d4dbc9d85df4…
2026-11-14 07:37:172026-10N018578-003SSD AF1%CREAM / TOPICAL1990-07-11d4dbc9d85df4…
2026-10-15 13:18:302026-09N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25c2088c7a36db…
2026-10-15 13:18:302026-09N018578-003SSD AF1%CREAM / TOPICAL1990-07-11c2088c7a36db…
2026-09-14 22:38:342026-08N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2584e616aacf4f…
2026-09-14 22:38:342026-08N018578-003SSD AF1%CREAM / TOPICAL1990-07-1184e616aacf4f…
2026-08-18 06:07:402026-07N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25caaa826d4ba7…
2026-08-18 06:07:402026-07N018578-003SSD AF1%CREAM / TOPICAL1990-07-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N018578-003SSD AF1%CREAM / TOPICAL1990-07-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018578-003SSD AF1%CREAM / TOPICAL1990-07-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N018578-003SSD AF1%CREAM / TOPICAL1990-07-116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018578-003SSD AF1%CREAM / TOPICAL1990-07-11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018578-003SSD AF1%CREAM / TOPICAL1990-07-11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018578-003SSD AF1%CREAM / TOPICAL1990-07-1103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-252680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018578-003SSD AF1%CREAM / TOPICAL1990-07-112680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-255bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018578-003SSD AF1%CREAM / TOPICAL1990-07-115bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018578-003SSD AF1%CREAM / TOPICAL1990-07-11d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25d06236e962d9…
2024-10-29 15:01 UTC2024-10N018578-003SSD AF1%CREAM / TOPICAL1990-07-11d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-2579d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018578-003SSD AF1%CREAM / TOPICAL1990-07-1179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-25301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018578-003SSD AF1%CREAM / TOPICAL1990-07-11301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-251e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018578-003SSD AF1%CREAM / TOPICAL1990-07-111e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018578-001SSD1%CREAM / TOPICALABRLD, RS1982-02-258072bd15b7f6…
2024-05-31 18:47 UTC2024-05N018578-003SSD AF1%CREAM / TOPICAL1990-07-118072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018578-001SSD1%CREAM / TOPICALAB1982-02-255c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018578-003SSD AF1%CREAM / TOPICAL1990-07-115c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018578-001SSD1%CREAM / TOPICALAB1982-02-255d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N018578-003SSD AF1%CREAM / TOPICAL1990-07-115d02ea3f76ae…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N018578-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09N018578-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08N018578-001AB184e616aacf4f…
2026-08-18 06:07:402026-07N018578-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018578-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018578-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N018578-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018578-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018578-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018578-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018578-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018578-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018578-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018578-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018578-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018578-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018578-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018578-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018578-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018578-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018578-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018578-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018578-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018578-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018578-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03N018578-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018578-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018578-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018578-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09N018578-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07N018578-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018578-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018578-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018578-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018578-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018578-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018578-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018578-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05N018578-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01N018578-001AB13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
1f879e75-4324-497e-920c-da822c06bcdbf81457dc-2671-458f-8ed5-b45528e6aa172012-05-02Warnings, Adverse reactionsExact identifier
spl id: 1f879e75-4324-497e-920c-da822c06bcdb
spl set id: f81457dc-2671-458f-8ed5-b45528e6aa17

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.